Expansion Opportunity PCI Pharma Services is actively expanding its U.S. sterile fill-finish, drug-device delivery capabilities and has announced investments exceeding $1B, including new CoE facilities in Bedford NH and León Spain, plus a San Diego high-speed RTU filling line. This indicates strong capacity growth and appetite for new CDMO partnerships, suggesting opportunities for LSNE to engage on development and supply collaborations during or after PCI’s expansion.

Bedford CoE Synergy PCI is investing in Development Centers of Excellence (CoE) in Bedford, NH and León, Spain, aligning with a strategy to optimize development and manufacturing workflows. LSNE, with on-site development, lyophilization, and cGMP capabilities, can position as a complementary partner for early-stage formulation development, cycle optimization, and Lyophilization services within PCI’s expanded ecosystem.

Lyophilization Focus LSNE’s core capabilities in aseptic fill finish and lyophilization match PCI’s expanded emphasis on sterile fill-finish and device integrations. Marketing the ability to support development-to-commercial lyophilized products and to provide feasibility work could create a compelling joint value proposition for PCI’s customers needing reliable small-to-medium batch production.

Regulatory Readiness LSNE highlights a proven regulatory history and cGMP compliance across clinical to commercial manufacturing. This can help PCI demonstrate a broader regulatory-supported supply network to customers during PCI’s growth wave, presenting a sales angle focused on risk mitigation, uninterrupted material supply, and faster time-to-market.

Technology Alignment PCI’s investments span advanced manufacturing assets and digital tools, with a technology stack that includes standards like NIST Cybersecurity Framework. Position LSNE as a compatible partner that can contribute with robust QA, development optimization, and secure, compliant manufacturing partnerships that fit PCI’s scale and modernization goals.